Nimotuzumab in Children With HGG

This study has been completed.
Sponsor:
Collaborators:
Children`s Medical Hospital, University of Bonn, Germany
University of Wuerzburg
Dept. of Statistics, University of Dortmund, Germany
CRM Biometrics GmbH, Rheinbach, Germany
Heinrich-Heine University, Duesseldorf
Hospital for Children and Adolescents, Augsburg, Germany
Dr. von Haunersches Children's Medical Hospital, University of Munich, Germany
Children`s Medical Hospital, University of Homburg/Saar, Homburg/Saar, Germany
Children`s Medical Hospital, Medical School Hannover, Hannover, Germany
Children's Medical Hospital, University of Essen, Essen, Germany
Dept. of Neuropediatrics and Muscle Disorders, University of Freiburg, Germany
University of Cologne
Universitätsklinikum Hamburg-Eppendorf
University of Regensburg
Information provided by:
Oncoscience AG
ClinicalTrials.gov Identifier:
NCT00561873
First received: November 20, 2007
Last updated: NA
Last verified: November 2007
History: No changes posted

November 20, 2007
November 20, 2007
June 2004
Not Provided
Response rate according to RECIST criteria [ Time Frame: week 8, week 21 ]
Same as current
No Changes Posted
Progress free interval, Toxicity according to CTC criteria, Symptom control [ Time Frame: week 8, week 21 ]
Same as current
Not Provided
Not Provided
 
Nimotuzumab in Children With HGG
Phase-II-Study of Efficacy of OSAG 101 (Theraloc®) for Adolscent Patients With Recurrent High Grade Glioma

Determination of efficiency of nimotuzumab in children with high grade glioma.

High grade malignant gliomas are tumors grade III and IV according to WHO classification, that originate from oligodendroglia and astrocytes, where the latter are also known as anaplastic astrocytoma(WHO grade III) and glioblastoma(WHO grade IV). This also includes intrinsic pontine gliomas of adolescents, which are usually not documented histologically due to their localisation, but they have a similar clinical progress when compared to high grade malignant astrocytic tumors. Among various molecular alterations, malignant gliomas overexpress EGFR (epidermal growth factor) in nearly 50% of cases, which is particularly pronounced in glioblastoma.(Schlegel 2003) Standard therapy consists of radical surgery as extensive as medically responsible followed by radiotherapy dose of 60 Gy, which is aimed at the area with a safety margin. The long-term efficacy of additional chemotherapy has been a subject for controversy for several decades. The combination of all three treatment modalities in grade III tumors can lead to median survival times of 3-5 years in adults.

For this treatment group reports of 5 year recurrence free periods in 33-50% of cases have been reported in children and adolescents.

For glioblastoma(WHO grade IV) 5year recurrence free periods are 3% in elderly patients and 10-20% for adolescents.(Schlegel 2003) In German speaking territories chemotherapy with Cisplatin, Etoposid and Ifosfamid is used as a postoperative treatment option for adolescents and this disease.(Wolff HIT-GBM) In case of recurrence therapy choices are even more limited, thus if medically feasible the enrolment in clinical trials is an option.

In this study the aim is to use an antibody directed against the EGF-receptor to effect the proliferation of the tumor cells negatively. Pilot studies conducted in adults indicate that the median survival time for patients with malignant glioma can be prolonged by the antibody treatment.

Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample

children, adolescents

High Grade Glioma
Not Provided
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
45
February 2007
Not Provided

Inclusion Criteria:

  • Histologically confirmed diagnosis of high grade glioma (WHO III und IV) [not needed for intrinsic pontine glioma]
  • Progressive patients under primary therapy or first and second radiologically confirmed recurrence(MRI not older than 2 weeks) of high grade gliomas between the age of > 3 years < 20 years
  • Lack of curative standard therapy which is currently under investigation in a national GPOH-therapy optimization study
  • Sufficient haematological, renal and hepatic function (CTC Grad ≤ 2)
  • Disease measurable radiologicaly in at least one dimension
  • Life expectancy > 4 Weeks
  • Written declaration of consent of the parents/legal guardians and if possible of the child after prior information

Exclusion Criteria:

  • Curative therapy with an alternative method after diagnosis of progression and during this study
  • Prior administration of human or murine antibody
  • Pregnancy in girls of child-bearing age
Both
3 Years to 20 Years
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
NCT00561873
BN001-PED04
Yes
Not Provided
Oncoscience AG
  • Children`s Medical Hospital, University of Bonn, Germany
  • University of Wuerzburg
  • Dept. of Statistics, University of Dortmund, Germany
  • CRM Biometrics GmbH, Rheinbach, Germany
  • Heinrich-Heine University, Duesseldorf
  • Hospital for Children and Adolescents, Augsburg, Germany
  • Dr. von Haunersches Children's Medical Hospital, University of Munich, Germany
  • Children`s Medical Hospital, University of Homburg/Saar, Homburg/Saar, Germany
  • Children`s Medical Hospital, Medical School Hannover, Hannover, Germany
  • Children's Medical Hospital, University of Essen, Essen, Germany
  • Dept. of Neuropediatrics and Muscle Disorders, University of Freiburg, Germany
  • University of Cologne
  • Universitätsklinikum Hamburg-Eppendorf
  • University of Regensburg
Principal Investigator: Udo Bode, Prof. MD University Bonn
Oncoscience AG
November 2007

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP